Efficacy of combination of Ezetimibe 10 mg and rosuvastatin 2.5 mg versus rosuvastatin 5 mg monotherapy for hypercholesterolemia in patients with type 2 diabetes

Table 2 Serum lipid parameters and Patients achieving specified LDL-C target at baseline and after 12 weeks of treatment

Serum lipid parametes	Baseline	12 weeks	^*P value
LDL-C, mg/dL
Rosuva/Eze 2.5/10 mg	111 ± 26	75 ± 18	< 0.001
Rosuva 5 mg	112 ± 22	98 ± 22	< 0.001
sdLDL-C, mg/dL
Rosuva/Eze 2.5/10 mg	34 ± 11	22 ± 7	< 0.001
Rosuva 5 mg	34 ± 11	28 ± 11	0.001
MDA-LDL, U/L
Rosuva/Eze 2.5/10 mg	112 ± 29	86 ± 22	< 0.001
Rosuva 5 mg	117 ± 34	100 ± 30	0.003
HDL-C, mg/dL
Rosuva/Eze 2.5/10 mg	57 ± 16	57 ± 16	0.861
Rosuva 5 mg	56 ± 11	58 ± 13	0.185
LDL/HDL ratio
Rosuva/Eze 2.5/10 mg	2.1 ± 0.8	1.4 ± 0.4	< 0.001
Rosuva 5 mg	2.0 ± 0.5	1.8 ± 0.5	< 0.001
TG, mg/dL
Rosuva/Eze 2.5/10 mg	147 ± 71	118 ± 56	0.001
Rosuva 5 mg	147 ± 79	136 ± 68	0.700
RLP-C, mg/dL
Rosuva/Eze 2.5/10 mg	4.9 ± 2.9	3.0 ± 1.1	< 0.001
Rosuva 5 mg	4.7 ± 2.5	3.7 ± 1.4	0.004
Patients achieveing specified LDL-C target	Baseline	12 weeks
Patients achieving LDL-C < 80, n (%)
Rosuva/Eze 2.5/10 mg	0 (0)	24 (61.5)^†
Rosuva 5 mg	0 (0)	8 (22.2)
Patients achieving LDL-C < 100, n (%)
Rosuva/Eze 2.5/10 mg	17 (43.6)	35 (89.7)^†
Rosuva 5 mg	11 (30.6)	21 (58.3)

Data are mean ± SD, n (%). Rosuva Rosuvastatin, Eze Ezetimibe, LDL Low-density lipoprotein cholesterol, sdLDL-C Small dense low-density lipoprotein cholesterol, MDA-LDL Malondialdehyde-modified low-density lipoprotein, sdLDL-C Small dense low-density lipoprotein cholesterol, HDL-C High-density lipoprotein cholesterol, TG Triglycerides, RLP-C Remnant-like particle cholesterol.
There were no significant differences among each baseline values.
*P values are for differences between baseline with 12 week.
^†P <0.01 for determine the association between-treatment difference, the Fisher’s exact test was used.